{'fraction_non_alphanumeric': 0.0259222333000997, 'fraction_numerical': 0.0, 'mean_word_length': 5.562091503267974, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Disease-modifying treatment of asthma: role of omalizumab

In the past years, we have seen a paradigm shift from symptomatic to disease-modifying approach to the treatment of chronic diseases. The treatment of asthma, which is a chronic disease, is no exception to this shift. Although the available therapies for asthma have been traditionally identified as either “controllers” or “relievers”, this dichotomous classification does not address the therapeutic potential to modify the underlying disease. The disease-modifying therapy for asthma can be defined either as airway remodeling or as modifying the disease's natural course. Among the biological therapies, the disease-modifying effect of omalizumab was studied most comprehensively. Some studies of other biological therapies for severe asthma (mepolizumab, benralizumab) also addressed the airway remodeling effect. A further study of the disease-modifying therapy should help gain a deeper understanding of its potential in managing asthma.